pbs_code
stringlengths 5
6
| drug
stringclasses 15
values | brand
stringclasses 29
values | formulation
stringclasses 35
values | indication
stringclasses 7
values | treatment_phase
stringclasses 53
values | streamlined_code
stringclasses 33
values | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | schedule_code
int64 4.03k
4.03k
| schedule_year
int64 2.02k
2.02k
| schedule_month
stringclasses 1
value |
---|---|---|---|---|---|---|---|---|---|---|---|---|
13308K | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Continuing treatment | 14154 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
13757C | tofacitinib | Xeljanz | Tablet 5 mg | juvenile idiopathic arthritis | Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
9034L | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11516D | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11516D | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | non-radiographic axial spondyloarthritis | Continuing treatment | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10767Q | ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
10767Q | ustekinumab | Stelara | Injection 45 mg in 0.5 mL | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13720D | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13065P | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled syringe | ankylosing spondylitis | Balance of supply (including switching formulation) where the full duration of treatment available under a particular treatment phase was not requested in the preceding prescription | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12217B | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12217B | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12217B | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12217B | ixekizumab | Taltz | Injection 80 mg in 1 mL single dose pre-filled pen | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3428K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3428K | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled syringe | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11375Q | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11375Q | golimumab | Simponi | Injection 50 mg in 0.5 mL single use pre-filled pen | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3449M | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Continuing Treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
3449M | etanercept | Enbrel | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | juvenile idiopathic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
13223Y | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
13223Y | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled pen | juvenile idiopathic arthritis | Subsequent continuing treatment | 11604 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
11498E | infliximab | Inflectra | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11498E | infliximab | Renflexis | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11498E | infliximab | Remicade | Powder for I.V. infusion 100 mg | psoriatic arthritis | Subsequent continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11197H | etanercept | Enbrel | Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Remicade | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Inflectra | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6448J | infliximab | Renflexis | Powder for I.V. infusion 100 mg | ankylosing spondylitis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
13228F | adalimumab | Humira | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
13228F | adalimumab | Yuflyma | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
13228F | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
13315T | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | juvenile idiopathic arthritis | Continuing treatment | 14179 | true | STREAMLINED | Private | 4,030 | 2,024 | AUGUST |
13047Q | infliximab | Remsima SC | Solution for injection 120 mg in 1 mL pre-filled syringe | psoriatic arthritis | Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Remicade | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
6397Q | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,030 | 2,024 | AUGUST |
11675L | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Continuing treatment | null | false | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
11675L | tofacitinib | Xeljanz | Tablet 5 mg | psoriatic arthritis | Continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12094M | tocilizumab | Actemra ACTPen | Injection 162 mg in 0.9 mL single use pre-filled pen | juvenile idiopathic arthritis | Balance of supply for Initial treatment - Initial 1 (new patient) or Initial 2 (retrial or recommencement of treatment after a break of less than 12 months) or Initial 3 (recommencement of treatment after a break of more than 12 months) - in a patient of any weight being administered a subcutaneous form of this biological medicine | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |
12355G | adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
12355G | adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
12355G | adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
12355G | adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
12355G | adalimumab | Idacio | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Continuing treatment | 14136 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
13723G | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13723G | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13723G | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13723G | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13723G | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13723G | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13723G | infliximab | Inflectra | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13723G | infliximab | Renflexis | Powder for I.V. infusion 100 mg | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13305G | tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | juvenile idiopathic arthritis | Continuing treatment | 14164 | true | STREAMLINED | Public | 4,030 | 2,024 | AUGUST |
13735X | certolizumab pegol | Cimzia | Injection 200 mg in 1 mL single use pre-filled syringe | rheumatoid arthritis | Subsequent continuing treatment | 14499 | true | STREAMLINED | Any | 4,030 | 2,024 | AUGUST |
12775J | tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial treatment - Initial 4 (Temporary listing - change of treatment from another biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab) | null | true | AUTHORITY_REQUIRED | Public | 4,030 | 2,024 | AUGUST |
13704G | adalimumab | Adalicip | Injection 40 mg in 0.4 mL pre-filled syringe | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | true | AUTHORITY_REQUIRED | Any | 4,030 | 2,024 | AUGUST |